Intelligence Report · ~12 min read
Sagent Pharmaceuticals Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Aug 5, 2026
Confidence
Moderate Confidence · 76%
Evidence
8 items
Sources
8
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Sagent Pharmaceuticals maintains an active intelligence profile across Infectious Disease, Antibiotic. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 76% across 2 tracked sources. Highest-priority development: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sagent Pharmaceuticals.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 36 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: Moderate.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Moderate Confidence · 65%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Grants AP Status for Clindamycin Phosphate ANDA090109
Infectious Disease · Antibiotic
- Sagent Pharmaceuticals' Clindamycin Phosphate ANDA090108 Receives AP Status
Infectious Disease · Antibiotic